DE60105381D1 - Valproat-Formulierungen mit gesteuerter Freigabe - Google Patents

Valproat-Formulierungen mit gesteuerter Freigabe

Info

Publication number
DE60105381D1
DE60105381D1 DE60105381T DE60105381T DE60105381D1 DE 60105381 D1 DE60105381 D1 DE 60105381D1 DE 60105381 T DE60105381 T DE 60105381T DE 60105381 T DE60105381 T DE 60105381T DE 60105381 D1 DE60105381 D1 DE 60105381D1
Authority
DE
Germany
Prior art keywords
valproate
composition
controlled release
significantly lower
cmax
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60105381T
Other languages
English (en)
Other versions
DE60105381T2 (de
Inventor
Yihong Qiu
Daniel J Bollinger
Sandeep Dutta
Howard S Cheskin
Kevin R Engh
Richard P Poska
Kenneth W Sommerville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/748,566 external-priority patent/US6528090B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of DE60105381D1 publication Critical patent/DE60105381D1/de
Application granted granted Critical
Publication of DE60105381T2 publication Critical patent/DE60105381T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE60105381T 2000-12-22 2001-12-21 Valproat-Formulierungen mit gesteuerter Freigabe Expired - Lifetime DE60105381T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US748566 1991-08-21
US877682 1997-06-17
US09/748,566 US6528090B2 (en) 1998-12-18 2000-12-22 Controlled release formulation of divalproex sodium
US09/877,682 US20020025341A1 (en) 1998-12-18 2001-06-08 Controlled release formulation of divalproex sodium
CA002399532A CA2399532A1 (en) 1998-12-18 2002-08-23 Controlled release formulation of divalproex sodium

Publications (2)

Publication Number Publication Date
DE60105381D1 true DE60105381D1 (de) 2004-10-14
DE60105381T2 DE60105381T2 (de) 2005-09-29

Family

ID=32930833

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60105381T Expired - Lifetime DE60105381T2 (de) 2000-12-22 2001-12-21 Valproat-Formulierungen mit gesteuerter Freigabe

Country Status (10)

Country Link
US (1) US20020025341A1 (de)
EP (1) EP1216704B1 (de)
AT (1) ATE275398T1 (de)
AU (1) AU2002239260A1 (de)
CA (1) CA2399532A1 (de)
DE (1) DE60105381T2 (de)
ES (1) ES2228762T3 (de)
PT (1) PT1216704E (de)
TR (1) TR200402549T4 (de)
WO (1) WO2002051401A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071421A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds
WO2006025029A2 (en) * 2004-08-31 2006-03-09 Ranbaxy Laboratories Limited Extended release composition of divalproex
EP2181708A1 (de) 2008-10-31 2010-05-05 Universitat Autonoma de Barcelona Verwendung von Valproat zur Reduktion der CHOP-Spiegel, insbesondere ein einem Säugetier mit SCI
EP2403487A2 (de) * 2009-03-04 2012-01-11 Fdc Limited Orale darreichungsformen mit verzögerter freisetzung für wasserlösliche arzneimittel
CN102895201B (zh) * 2011-07-26 2014-09-10 北大方正集团有限公司 丙戊酸半钠片剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU83729A1 (fr) * 1981-11-04 1983-09-01 Galephar Sels d'acide valproique,leur preparation et leur utilisation
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
FR2643556B1 (fr) * 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
EP0664118B1 (de) * 1991-10-04 1999-08-25 Yoshitomi Pharmaceutical Industries, Ltd. Tablette mit verzögerter freisetzung
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US6528090B2 (en) * 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US6511678B2 (en) * 1998-12-18 2003-01-28 Abbott Laboratories Controlled release formulation of divalproex sodium
KR20010101295A (ko) * 1998-12-18 2001-11-14 스티븐 에프. 웨인스톡 디발프로엑스 나트륨의 조절-방출성 제형물
US6419953B1 (en) * 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
US6713086B2 (en) * 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
US6150410A (en) * 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
ATE424191T1 (de) * 1999-02-04 2009-03-15 Abbott Lab Ph-unabhängige pharmazeutische formulierungen mit verlängerter freisetzung

Also Published As

Publication number Publication date
ATE275398T1 (de) 2004-09-15
US20020025341A1 (en) 2002-02-28
ES2228762T3 (es) 2005-04-16
DE60105381T2 (de) 2005-09-29
EP1216704B1 (de) 2004-09-08
AU2002239260A1 (en) 2002-07-08
EP1216704A1 (de) 2002-06-26
WO2002051401A3 (en) 2003-01-09
WO2002051401A2 (en) 2002-07-04
PT1216704E (pt) 2004-11-30
CA2399532A1 (en) 2004-02-23
TR200402549T4 (tr) 2004-12-21

Similar Documents

Publication Publication Date Title
CY1105908T1 (el) Στοματικως αποσαθρουμενα δισκια που πepιλαμβανουν βενζιμιδαζολιο
NZ314442A (en) Extended release formulation comprising venlafaxine hydrochloride, film coating composition
DK1213015T3 (da) Oralt farmaceutisk præparat med forsinket frigivelse af protonpumpeinhibitorer
CA2301378A1 (en) Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
DK0841904T3 (da) Orale farmaceutiske præparater med forsinket frigivelse af reversible protonpumpeinhibitorer
BG104620A (en) Oral pharmaceutical extended release dosage form
IL129870A (en) Sustained release tablets having an insoluble active ingredient therein
TWI235068B (en) Sustained-release pharmaceutical composition
HUP0301591A2 (hu) Szabályozott hatóanyag-leadású hidrokodon-készítmények
DK0808156T3 (da) Præparater omfattende nanopartikler af NSAID
TNSN03108A1 (en) Once-a-day oxycodone formulations
HUP9900231A2 (hu) Szabályozott kibocsátású készítmények gyengén oldódó gyógyszerekhez
DE69622510D1 (de) Nifedipinzubereitung mit langanhaltender Freisetzung
CO5160287A1 (es) Formulacion de liberacion controlada de divalproex sodico
AR021806A1 (es) COMPOSICIoN FARMACÉUTICA EN FORMA DE TABLETA QUE COMPRENDE ENTACAPONA Y MÉTODO DE PREPARACIoN.
DE59908764D1 (de) Agitationsunabhängige pharmazeutische multiple-unit-retardzubereitungen und verfahren zu ihrer herstellung
ATE430561T1 (de) Chronotherapeutische diltiazem formulierungen und deren verabreichung
SI1105105T1 (sl) Oralna dajalna oblika za piridin-2-ilmetilsulfinil-1J-benzimidazole
DE60105381D1 (de) Valproat-Formulierungen mit gesteuerter Freigabe
SE9501671D0 (sv) Method and composition for prevention of posterior capsule opacification
CA2341805A1 (en) Controlled release formulation of divalproex sodium
CA2341803A1 (en) Controlled release formulation of divalproex sodium
DK0557244T3 (da) Dosisformer med forlænget afgivelse af aktivt stof
CY1115706T1 (el) Σκευασματα οξυκωδονης για μια φορα ημερησιως

Legal Events

Date Code Title Description
8364 No opposition during term of opposition